Evidence map›Paper›PMID 42610641›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Reorganization of Innate Immune Cell Lipid Profiles by Bioinspired Meroterpenoids to Limit Inflammation.

Lorenz Waltl, David Holubek, Klaus Speck, Raphael Wildermuth, Franz-Lucas Haut, Stephan Permann, Immanuel Plangger, Christian Steinborn, Zhigang Rao, Danilo D'Avino and 11 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lorenz WaltlMichael Popp Institute and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-0385-7216
David HolubekInstitute of Pharmaceutical Sciences and Excellence Field BioHealth, NAWI Graz, University of Graz., Graz, Austria.ORCID https://orcid.org/0009-0000-0220-5876
Klaus SpeckDepartment of Organic Chemistry and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.
Raphael WildermuthDepartment of Organic Chemistry and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.
Franz-Lucas HautDepartment of Organic Chemistry and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0003-2091-6270
Stephan PermannMichael Popp Institute and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-8236-3897
Immanuel PlanggerDepartment of Organic Chemistry and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-9912-5377
Christian SteinbornDepartment of Organic Chemistry and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.
Zhigang RaoMichael Popp Institute and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-9918-9100
Danilo D'AvinoDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0000-0002-6350-5191
Ida CerquaDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0000-0002-4363-7728
Julia StadlerInstitute of Pharmaceutical Sciences and Excellence Field BioHealth, NAWI Graz, University of Graz., Graz, Austria.
Fiorentina RoviezzoDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0000-0003-1582-7396
Peter SchlenkeClinical Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
Anita SillerCentral Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria.ORCID https://orcid.org/0009-0003-7860-7144
Harald SchennachCentral Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria.ORCID https://orcid.org/0009-0005-8536-8780
Solveigh C KoeberleInstitute of Pharmaceutical Sciences and Excellence Field BioHealth, NAWI Graz, University of Graz., Graz, Austria.ORCID https://orcid.org/0000-0002-8008-494X
Eva-Maria Pferschy-WenzigInstitute of Pharmaceutical Sciences and Excellence Field BioHealth, NAWI Graz, University of Graz., Graz, Austria.ORCID https://orcid.org/0000-0001-8327-0732
Antonietta RossiDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0000-0002-3237-2584
Thomas MagauerDepartment of Organic Chemistry and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0003-1290-9556
Andreas KoeberleMichael Popp Institute and Center for Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0001-6269-5088

Funding

Austrian Science Fund 10.55776/I4968Austrian Science Fund 10.55776/P36299Austrian Science Fund 10.55776/PAT9018824Center for Molecular BiosciencesEuropean Research Council under the European Union's Horizon 2020 research and innovation program 101000060European Research Council under the European Union's Horizon 2020 research and innovation program 714049Ministero dell'Università e della Ricerca P2022CNPH8
6 · The paper itself

Abstract

Lipidomics-guided screening of unexplored natural product chemical space provides access to small molecules that globally reprogram cellular lipid profiles. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp. reshapes immune cell lipidomes, shifting them from pro-inflammatory toward anti-inflammatory and pro-resolving mediators. Structural variation yielded derivatives that context-dependently inhibit leukotriene biosynthesis to varying extents while upregulating pro-resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, sphingosine-1-phosphate, and others in resting and activated innate immune cells in vitro, as well as in self-resolving murine peritonitis and fibrosis in vivo. Mechanistically, meroterpenoids target 5-lipoxygenase or 5-lipoxygenase-activating protein, promote 15-lipoxygenase-1 translocation to particulate sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid from neutral lipids to specific phospholipids while increasing free arachidonic acid levels. Furthermore, meroterpenoids reprogram immune cell lipid metabolism by reducing neutral lipid, triacylglycerol, and cholesteryl ester levels, a shift that correlates with a lower capacity for leukotriene biosynthesis and is phenocopied by inhibiting sterol-O-acyltransferase, which catalyzes cholesterol esterification for storage, and diacylglycerol acyltransferase-1/2, which catalyze the final step in triacylglycerol biosynthesis. In conclusion, specific meroterpenoids exert anti-inflammatory effects by rewiring lipid mediator biosynthesis through structure-controlled switches in lipid mediator classes, and an unexpected link between lipogenesis and inflammation.

Indexed as

inflammationlipid mediatorslipidomicslipoxygenasesmolecular mechanismsnatural productspharmacology

Identifiers

PMID42610641
PMCPMC13483160

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.